Prostate Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
MRI-Guided Focal Laser Therapy for Low-risk Prostate Cancer
(Posted: 07/10/2012) - In this pilot study, men diagnosed with or suspected of having low-risk prostate cancer will undergo advanced MRI techniques to guide a biopsy to the tumor area; subsequently, they will be treated using MRI-guided focal laser ablation therapy to only that area of the prostate.
Inhibiting Tumor Angiogenesis in Metastatic Hormone-Refractory Prostate Cancer
(Posted: 04/05/2011) - In this NIH Clinical Center study, researchers will test whether treatment with a novel monoclonal antibody, TRC105, that targets a protein highly expressed on the surface of tumor blood vessels improves the outcome of men with metastatic castration-resistant prostate cancer.
Combining Vaccine and Antiandrogen Therapy for Prostate Cancer
(Posted: 09/21/2010) - In this clinical trial, men with castration-resistant, nonmetastatic prostate cancer who are undergoing androgen deprivation therapy will be randomly assigned to undergo antiandrogen treatment with the FDA-approved drug flutamide with or without the addition of a PSA-targeting vaccine called PROSTVAC/PSA-TRICOM.
Inhibiting Angiogenesis in Metastatic Castration-Resistant Prostate Cancer
(Posted: 06/29/2010) - In this trial, patients with metastatic castration-resistant prostate cancer who have received no treatment for metastatic disease will be treated with docetaxel, prednisone, bevacizumab, and lenalidomide.
Vaccine Therapy for Patients with Progressive Stage D0 Prostate Cancer
(Posted: 03/23/2010) - In this phase I trial, researchers are evaluating the safety of a vaccine to treat stage D0 prostate cancer and whether the body’s immune system will respond to it by producing T lymphocytes that will selectively attack cancer cells.
(Posted: 07/10/2012) - In this pilot study, men diagnosed with or suspected of having low-risk prostate cancer will undergo advanced MRI techniques to guide a biopsy to the tumor area; subsequently, they will be treated using MRI-guided focal laser ablation therapy to only that area of the prostate.
Inhibiting Tumor Angiogenesis in Metastatic Hormone-Refractory Prostate Cancer
(Posted: 04/05/2011) - In this NIH Clinical Center study, researchers will test whether treatment with a novel monoclonal antibody, TRC105, that targets a protein highly expressed on the surface of tumor blood vessels improves the outcome of men with metastatic castration-resistant prostate cancer.
Combining Vaccine and Antiandrogen Therapy for Prostate Cancer
(Posted: 09/21/2010) - In this clinical trial, men with castration-resistant, nonmetastatic prostate cancer who are undergoing androgen deprivation therapy will be randomly assigned to undergo antiandrogen treatment with the FDA-approved drug flutamide with or without the addition of a PSA-targeting vaccine called PROSTVAC/PSA-TRICOM.
Inhibiting Angiogenesis in Metastatic Castration-Resistant Prostate Cancer
(Posted: 06/29/2010) - In this trial, patients with metastatic castration-resistant prostate cancer who have received no treatment for metastatic disease will be treated with docetaxel, prednisone, bevacizumab, and lenalidomide.
Vaccine Therapy for Patients with Progressive Stage D0 Prostate Cancer
(Posted: 03/23/2010) - In this phase I trial, researchers are evaluating the safety of a vaccine to treat stage D0 prostate cancer and whether the body’s immune system will respond to it by producing T lymphocytes that will selectively attack cancer cells.
